APA (7th ed.) Citation

Alan, O., Kuzhan, O., Koca, S., Telli, T. A., Basoglu, T., Ercelep, O., . . . Yumuk, P. F. (2020). How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature. Journal of Oncology Pharmacy Practice, 26(4), 1011. https://doi.org/10.1177/1078155219879757

Chicago Style (17th ed.) Citation

Alan, Ozkan, et al. "How Long Should We Continue Crizotinib in ALK Translocation-positive Inflammatory Myofibroblastic Tumors? Long-term Complete Response with Crizotinib and Review of the Literature." Journal of Oncology Pharmacy Practice 26, no. 4 (2020): 1011. https://doi.org/10.1177/1078155219879757.

MLA (9th ed.) Citation

Alan, Ozkan, et al. "How Long Should We Continue Crizotinib in ALK Translocation-positive Inflammatory Myofibroblastic Tumors? Long-term Complete Response with Crizotinib and Review of the Literature." Journal of Oncology Pharmacy Practice, vol. 26, no. 4, 2020, p. 1011, https://doi.org/10.1177/1078155219879757.